{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:01:16Z","timestamp":1694397676690},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s11899-009-0025-2","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T07:16:19Z","timestamp":1254294979000},"page":"189-195","source":"Crossref","is-referenced-by-count":3,"title":["Vaccination strategies in follicular lymphoma"],"prefix":"10.1007","volume":"4","author":[{"given":"Shibichakravarthy","family":"Kannan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"25_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.blre.2004.09.001","volume":"19","author":"M.K. Gandhi","year":"2005","unstructured":"Gandhi MK, Marcus RE: Follicular lymphoma: time for a re-think? Blood Rev 2005, 19:165\u2013178.","journal-title":"Blood Rev"},{"key":"25_CR2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W. Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106, 3725\u20133732.","journal-title":"Blood"},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"R.I. Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005, 23:8447\u20138452.","journal-title":"J Clin Oncol"},{"key":"25_CR4","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1200\/JCO.2004.04.020","volume":"22","author":"M.S. Czuczman","year":"2004","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin\u2019s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711\u20134716.","journal-title":"J Clin Oncol"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","volume":"311","author":"S.J. Horning","year":"1984","unstructured":"Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med 1984, 311:1471\u20131475.","journal-title":"N Engl J Med"},{"key":"25_CR6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"S.S. Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159\u20132169.","journal-title":"N Engl J Med"},{"key":"25_CR7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/1078-0432.CCR-06-1734","volume":"13","author":"B.E. Wahlin","year":"2007","unstructured":"Wahlin BE, Sander B, Christensson B, Kimby E: CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007, 13:388\u2013397.","journal-title":"Clin Cancer Res"},{"key":"25_CR8","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","volume":"24","author":"T. Alvaro","year":"2006","unstructured":"Alvaro T, Lejeune M, Salvad\u00f3 MT, et al.: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006, 24:5350\u20135357.","journal-title":"J Clin Oncol"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V89.10.3806","volume":"89","author":"J.L. Schultze","year":"1997","unstructured":"Schultze JL, Seamon MJ, Michalak S, et al.: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997, 89:3806\u20133816.","journal-title":"Blood"},{"key":"25_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2007.09.006","volume":"331","author":"S.T. Lee","year":"2008","unstructured":"Lee ST, Liu S, Radvanyi L, et al.: A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 2008, 331:13\u201326.","journal-title":"J Immunol Methods"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/254714a0","volume":"254","author":"G.T. Stevenson","year":"1975","unstructured":"Stevenson GT, Stevenson FK: Antibody to a molecularly defined antigen confined to a tumour cell surface. Nature 1975, 254:714\u2013716.","journal-title":"Nature"},{"key":"25_CR12","first-page":"2268","volume":"36","author":"G.T. Stevenson","year":"1977","unstructured":"Stevenson GT, Elliott EV, Stevenson FK: Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed Proc 1977, 36:2268\u20132271.","journal-title":"Fed Proc"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jnci\/56.4.735","volume":"56","author":"P.M. Freedman","year":"1976","unstructured":"Freedman PM, Autry JR, Tokuda S, Williams RC Jr: Tumor immunity induced by preimmunization with BALB\/c mouse myeloma protein. J Natl Cancer Inst 1976, 56:735\u2013740.","journal-title":"J Natl Cancer Inst"},{"key":"25_CR14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4049\/jimmunol.138.4.1289","volume":"138","author":"M.S. Kaminski","year":"1987","unstructured":"Kaminski MS, Kitamura K, Maloney DG, et al.: Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987, 138:1289\u20131296.","journal-title":"J Immunol"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1073\/pnas.93.20.10972","volume":"93","author":"L.W. Kwak","year":"1996","unstructured":"Kwak LW, Young HA, Pennington RW, et al.: Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte\/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996, 93:10972\u201310977.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25_CR16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","volume":"327","author":"L.W. Kwak","year":"1992","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209\u20131215.","journal-title":"N Engl J Med"},{"key":"25_CR17","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","volume":"89","author":"F.J. Hsu","year":"1997","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial. Blood 1997, 89:3129\u20133135.","journal-title":"Blood"},{"key":"25_CR18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","volume":"5","author":"M. Bendandi","year":"1999","unstructured":"Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171\u20131177.","journal-title":"Nat Med"},{"key":"25_CR19","doi-asserted-by":"crossref","unstructured":"Santos C, Stern L, Katz L, et al.: BiovaxID vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial [abstract 2441]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2441.","DOI":"10.1182\/blood.V106.11.2441.2441"},{"key":"25_CR20","first-page":"146","volume":"6","author":"D.L. Longo","year":"2000","unstructured":"Longo DL, Duffey PL, Gribben JG, et al.: Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J 2000, 6:146\u2013150.","journal-title":"Cancer J"},{"key":"25_CR21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","volume":"98","author":"S. Inoges","year":"2006","unstructured":"Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al.: Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst 2006, 98:1292\u20131301.","journal-title":"J Natl Cancer Inst"},{"key":"25_CR22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","volume":"11","author":"S.S. Neelapu","year":"2005","unstructured":"Neelapu SS, Kwak LW, Kobrin CB, et al.: Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986\u2013991.","journal-title":"Nat Med"},{"key":"25_CR23","first-page":"772","volume":"106","author":"O. Koc","year":"2005","unstructured":"Koc O, Redfern C, Wiernik P, et al.: Extended follow-up and analysis with central radiological review of patients receiving FavId [abstract 772]. Blood (ASH Annual Meeting Abstracts) 2005, 106:772.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl","key":"25_CR24","first-page":"18s","volume":"27","author":"S.J. Schuster","year":"2009","unstructured":"Schuster SJ, Neelapu SS, Gause BL, et al.: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract 2]. J Clin Oncol 2009, 27(Suppl):18s.","journal-title":"J Clin Oncol"},{"key":"25_CR25","doi-asserted-by":"crossref","unstructured":"Levy R, Robertson M, Ganjoo K, et al.: Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin\u2019s lymphoma (fNHL) [abstract LB-204]. In Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April 12\u201316, 2008.","DOI":"10.1158\/1538-7445.AM2008-LB-204"},{"key":"25_CR26","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","volume":"27","author":"A. Freedman","year":"2009","unstructured":"Freedman A, Neelapu SS, Nichols C, et al.: Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009, 27:3036\u20133043.","journal-title":"J Clin Oncol"},{"key":"25_CR27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","volume":"142","author":"H.J. Park","year":"2008","unstructured":"Park HJ, Neelapu SS: Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol 2008, 142:179\u2013191.","journal-title":"Br J Haematol"},{"key":"25_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W. Zou","year":"2005","unstructured":"Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263\u2013274.","journal-title":"Nat Rev Cancer"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"J.M. Timmerman","year":"2002","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517\u20131526.","journal-title":"Blood"},{"key":"25_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","volume":"113","author":"M. Nicola Di","year":"2009","unstructured":"Di Nicola M, Zappasodi R, Carlo-Stella C, et al.: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009, 113:18\u201327.","journal-title":"Blood"},{"key":"25_CR31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/3266","volume":"4","author":"C.A. King","year":"1998","unstructured":"King CA, Spellerberg MB, Zhu D, et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281\u20131286.","journal-title":"Nat Med"},{"key":"25_CR32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/6995","volume":"17","author":"T. Biragyn","year":"1999","unstructured":"Biragyn T, Tani K, Grimm MC, et al.: Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent anti-tumor immunity. Nat Biotech 1999, 17:253\u2013258.","journal-title":"Nat Biotech"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrc2326","volume":"8","author":"J. Rice","year":"2008","unstructured":"Rice J, Ottensmeier CH, Stevenson FK: DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108\u2013120.","journal-title":"Nat Rev Cancer"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2006-12-063594","volume":"109","author":"S.S. Neelapu","year":"2007","unstructured":"Neelapu SS, Gause BL, Harvey L, et al.: A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 2007, 109:5160\u20135163.","journal-title":"Blood"},{"key":"25_CR35","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"Z.Z. Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, et al.: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639\u20133646.","journal-title":"Blood"},{"key":"25_CR36","first-page":"309","volume":"112","author":"M. Foglietta","year":"2008","unstructured":"Foglietta M, Delgado D, Nattamai D, et al.: CD4+Foxp3+ regulatory T cells persist in high numbers in peripheral blood after induction of clinical remission with standard chemotherapy and suppress tumor-specific effector T cells in patients with follicular lymphoma [abstract 3778]. Blood (ASH Annual Meeting Abstracts) 2008, 112:309.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"25_CR37","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","volume":"115","author":"J. Dannull","year":"2005","unstructured":"Dannull J, Su Z, Rizzieri D, et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623\u20133633.","journal-title":"J Clin Invest"},{"key":"25_CR38","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"G.J. Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027\u20131034.","journal-title":"J Exp Med"},{"key":"25_CR39","first-page":"Abstract 2749","volume":"110","author":"D. Nattamai","year":"2007","unstructured":"Nattamai D, Neelapu SS: PD-1 expression is markedly upregulated on intratumoral CD4+ and CD8+ T cells in follicular lymphoma and is associated with T-cell exhaustion [abstract 2749]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 2749.","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"25_CR40","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R. Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, et al.: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044\u20133051.","journal-title":"Clin Cancer Res"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0025-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T23:41:36Z","timestamp":1685144496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0025-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}